3. Adrenergic Drugs

Overview and General Concepts of Adrenergic Drugs

  • Definitions and Terminology:

    • Sympathomimetics (Adrenergic Stimulants): Agonists and substances that produce physiological effects similar to those resulting from the stimulation of sympathetic nervous activity.

    • Sympatholytics (Antiadrenergics / Adrenergic-Blocking Agents): Antagonists and substances that decrease or inhibit sympathetic nervous activity.

  • Physiological Responses to Sympathetic ("Fight or Flight") Stimulation:

    • Acceleration of heart rate and lung action.

    • Relaxation of the urinary bladder.

    • Dilation of the pupil (mydriasis\text{mydriasis}).

    • Constriction of smooth muscle in blood vessels.

    • Inhibition of erection.

    • Decreased secretion from exocrine glands (including salivary and tear glands).

    • Opening-up (dilation) of respiratory tract airways.

    • Mobilization of energy stores (particularly fat and glucose) for muscular action.

Endogenous Catecholamines and Physicochemical Properties

  • Chemical Substructures:

    • Catechol: 1,2-dihydroxybenzene1,2\text{-dihydroxybenzene} (3′,4′-dihydroxybenzene3',4'\text{-dihydroxybenzene} ring system).

    • β-Phenylethylamine\beta\text{-Phenylethylamine}: Benzene ring attached to a two-carbon chain (β\beta and α\alpha carbons) terminating in an amine group.

    • Ethylamine: Two-carbon chain attached to an amine (-CH2-CH2-NH2\text{-CH}_2\text{-CH}_2\text{-NH}_2).

    • Catecholamine: Composite structure consisting of a catechol ring linked to an ethylamine side chain.

  • Endogenous Catecholamines:

    • Dopamine (DA): Catechol ring with an unsubstituted ethylamine chain.

      • Log P=0.12\text{Log } P = 0.12

    • Norepinephrine (NE / Noradrenaline): Catechol ring with a β-hydroxyl\beta\text{-hydroxyl} group and a primary amine.

      • Log P=−0.63\text{Log } P = -0.63

    • Epinephrine (E / Adrenaline): Catechol ring with a β-hydroxyl\beta\text{-hydroxyl} group and an N-methylN\text{-methyl} group (-NH-CH3\text{-NH-CH}_3).

      • Log P=0.28\text{Log } P = 0.28

      • pKa=9.9pK_a = 9.9

      • log D at pH 7=−2.75\text{log } D \text{ at pH } 7 = -2.75

  • General Physicochemical & Pharmacokinetic Properties:

    • All endogenous catecholamines are polar molecules.

    • Extensively metabolized by both Monoamine Oxidase (MAO\text{MAO}) and Catechol-O-methyltransferase (COMT\text{COMT}).

    • Orally inactive due to rapid enzymatic degradation.

    • Possess a very short duration of action (DOA\text{DOA}).

Biosynthesis and Neuronal Handling of Catecholamines

  • Biosynthetic Pathway:

    1. L-Tyrosine→Tyrosine Hydroxylase (TH)L-Dihydroxyphenylalanine (L-Dopa)\text{L-Tyrosine} \xrightarrow{\text{Tyrosine Hydroxylase (TH)}} \text{L-Dihydroxyphenylalanine (L-Dopa)}

    2. L-Dopa→L-Aromatic Amino Acid Decarboxylase (AADC) / DOPA DecarboxylaseDopamine (DA)+CO2\text{L-Dopa} \xrightarrow{\text{L-Aromatic Amino Acid Decarboxylase (AADC) / DOPA Decarboxylase}} \text{Dopamine (DA)} + \text{CO}_2

    3. Dopamine\text{Dopamine} is transported into vesicles via Vesicular Monoamine Transporter (VMAT\text{VMAT}) driven by an H+\text{H}^+ gradient.

    4. Dopamine→Dopamine β-Hydroxylase (DBH)Norepinephrine (NE)\text{Dopamine} \xrightarrow{\text{Dopamine } \beta\text{-Hydroxylase (DBH)}} \text{Norepinephrine (NE)}

    5. Norepinephrine→Phenylethanolamine N-Methyltransferase (PNMT / PENMT)Epinephrine (E)\text{Norepinephrine} \xrightarrow{\text{Phenylethanolamine N-Methyltransferase (PNMT / PENMT)}} \text{Epinephrine (E)} (utilizing S-Adenosyl Methionine (SAM)S\text{-Adenosyl Methionine (SAM)} as the methyl donor).

  • Neuronal Terminal Events & Pharmacological Interventions:

    • Tyrosine\text{Tyrosine} enters the presynaptic terminal via a Na+-dependent\text{Na}^+\text{-dependent} transporter.

    • Metyrosine: Inhibits Tyrosine Hydroxylase\text{Tyrosine Hydroxylase}, blocking the initial rate-limiting step of biosynthesis.

    • Reserpine: Inhibits VMAT\text{VMAT}, preventing vesicle storage and causing catecholamine depletion.

    • Calcium Channels: Action potentials trigger Ca2+\text{Ca}^{2+} influx through voltage-gated calcium channels, promoting vesicle fusion.

    • Exocytosis: Release of NE\text{NE}, ATP\text{ATP}, and peptides (P\text{P}) from vesicles into the synaptic cleft.

      • Exocytotic release is inhibited by Bretylium and Guanethidine.

    • Receptor Binding: Released NE\text{NE} acts on presynaptic autoreceptors/heteroreceptors and postsynaptic adrenoceptors.

    • Reuptake via NET: Norepinephrine Transporter (NET)\text{Norepinephrine Transporter (NET)} clears NE\text{NE} from the synapse back into the axon terminal.

      • NET\text{NET} is inhibited by Cocaine and Tricyclic Antidepressants.

Metabolism of Catecholamines by MAO and COMT

  • Monoamine Oxidase (MAO):

    • Localization: Mitochondrial enzyme.

    • Reaction: Oxidizes primary (-NH2\text{-NH}_2) or secondary (-NHR\text{-NHR}) amines into aldehydes (-CHO\text{-CHO}).

    • Norepinephrine\text{Norepinephrine} (R=HR = \text{H}) or Epinephrine\text{Epinephrine} (R=CH3R = \text{CH}_3) →MAO3′,4′-Dihydroxyphenyl-glycolaldehyde (DOPGAL)\xrightarrow{\text{MAO}} 3',4'\text{-Dihydroxyphenyl-glycolaldehyde (DOPGAL)}.

  • Catechol-O-Methyltransferase (COMT):

    • Reaction: Adds a methyl group to the 3′-hydroxyl3'\text{-hydroxyl} (3′-OH3'\text{-OH}) position of catechol substrates.

    • Norepinephrine\text{Norepinephrine} (R=HR = \text{H}) →COMTNormetanephrine\xrightarrow{\text{COMT}} \text{Normetanephrine} (R=HR = \text{H}).

    • Epinephrine\text{Epinephrine} (R=CH3R = \text{CH}_3) →COMTMetanephrine\xrightarrow{\text{COMT}} \text{Metanephrine} (R=CH3R = \text{CH}_3).

  • Downstream Enzymatic Transformations:

    • 3′,4′-Dihydroxyphenyl-glycolaldehyde (DOPGAL)→Aldehyde Dehydrogenase3′,4′-Dihydroxymandelic Acid3',4'\text{-Dihydroxyphenyl-glycolaldehyde (DOPGAL)} \xrightarrow{\text{Aldehyde Dehydrogenase}} 3',4'\text{-Dihydroxymandelic Acid} (Oxidation from aldehyde to carboxylic acid).

    • 3′,4′-Dihydroxyphenyl-glycolaldehyde (DOPGAL)→Aldehyde Reductase3′,4′-Dihydroxyphenylethylene Glycol3',4'\text{-Dihydroxyphenyl-glycolaldehyde (DOPGAL)} \xrightarrow{\text{Aldehyde Reductase}} 3',4'\text{-Dihydroxyphenylethylene Glycol} (Reduction from aldehyde to alcohol).

    • Normetanephrine\text{Normetanephrine} or Metanephrine\text{Metanephrine} →MAO + Aldehyde Dehydrogenase3′-Methoxy-4′-hydroxy-mandelic Acid\xrightarrow{\text{MAO + Aldehyde Dehydrogenase}} 3'\text{-Methoxy-}4'\text{-hydroxy-mandelic Acid} [also known as Vanillylmandelic Acid (VMA)].

    • Normetanephrine\text{Normetanephrine} or Metanephrine\text{Metanephrine} →MAO + Aldehyde Reductase3′-Methoxy-4′-hydroxy-phenylethylene Glycol\xrightarrow{\text{MAO + Aldehyde Reductase}} 3'\text{-Methoxy-}4'\text{-hydroxy-phenylethylene Glycol}.

  • Oxidation Levels Summary:

    • Alcohol (-OH\text{-OH}) ↔\leftrightarrow Aldehyde (-CHO\text{-CHO}) ↔\leftrightarrow Carboxylic Acid (-COOH\text{-COOH}).

    • Dehydrogenase enzymes catalyze oxidation; Reductase enzymes catalyze reduction.

  • Clinical Diagnostic Marker:

    • Vanillylmandelic Acid (VMA): Major final excretion end product of NE\text{NE} and E\text{E} metabolism.

    • Urinary VMA\text{VMA} levels are significantly elevated in patients with catecholamine-secreting tumors, such as the adrenal gland tumor pheochromocytoma.

Structure-Activity Relationships (SAR) of Phenylethylamine Agonists

  • Minimal Structural Requirements for Direct Activity:

    1. β-Phenylethylamine\beta\text{-Phenylethylamine} core.

    2. Catechol ring (or suitable aromatic modification).

    3. (1R)-hydroxyl group(1R)\text{-hydroxyl group} at the β-position\beta\text{-position}.

  • Stereochemistry at the β-Position\beta\text{-Position}:

    • The (R)-enantiomer(R)\text{-enantiomer} is substantially more active than the (S)-enantiomer(S)\text{-enantiomer}.

    • (R)-(-)-Epinephrine(R)\text{-(-)-Epinephrine} establishes a three-point receptor binding fit (hydrogen bonding via β-OH\beta\text{-OH}, ionic bonding via protonated amine, aromatic interaction).

    • (S)-(+)-Epinephrine(S)\text{-(+)-Epinephrine} lacks proper alignment for the β-hydroxyl\beta\text{-hydroxyl} hydrogen-bonding interaction.

  • Aromatic Ring Substitution SAR:

    • 3′,4′-diOH3',4'\text{-diOH} (Catechol): Confers both α\alpha and β\beta agonist activity. Substrate for COMT\text{COMT}, resulting in poor oral bioavailability and short DOA\text{DOA}. Highly hydrophilic, leading to poor CNS\text{CNS} penetration.

    • 3′,5′-diOH3',5'\text{-diOH} (Resorcinol ring, e.g., Metaproterenol): Increases β2\beta_2 selectivity. Resistant to COMT\text{COMT} metabolism, leading to increased absorption, higher oral activity, and longer DOA\text{DOA}.

    • 3′-CH2-OH,4′-OH3'\text{-CH}_2\text{-OH}, 4'\text{-OH} (e.g., Albuterol): Increases β2\beta_2 selectivity. Decreases COMT\text{COMT} degradation, leading to increased oral activity and prolonged DOA\text{DOA}.

    • 3′-OH3'\text{-OH} alone (e.g., Phenylephrine): Critical for selective α1\alpha_1 activity with almost no β\beta activity.

    • No Phenolic Substitution: Retains both α\alpha and β\beta activity; can act via direct or indirect (releasing) mechanisms.

  • Substrate Specificity for COMT:

    • Substrates: Catechol rings (3′,4′-diOH3',4'\text{-diOH}).

    • Non-Substrates: Monophenols (e.g., 3′-OH3'\text{-OH}) and Resorcinols (3′,5′-diOH3',5'\text{-diOH}).

  • Amine Substitution (R1R_1) SAR:

    • Must be primary (1∘1^\circ) or secondary (2∘2^\circ) amines. Tertiary (3∘3^\circ) and quaternary amines are inactive as agonists.

    • Increasing the size/bulk of the R1R_1 substituent:

      • Increases β\beta receptor activity and decreases α\alpha receptor activity.

      • Decreases inactivation by MAO\text{MAO}.

      • Increases oral bioavailability and DOA\text{DOA}.

      • An N-t-butylN\text{-t-butyl} group confers selective β2\beta_2 activity and significantly decreases MAO\text{MAO} degradation.

  • Receptor Subtype Targets:

    • β1-Receptors\beta_1\text{-Receptors}: Cardiac receptors (increase heart muscle contraction; antagonists used for hypertension).

    • β2-Receptors\beta_2\text{-Receptors}: Tracheal/bronchial receptors (smooth muscle relaxation; agonists used for asthma).

Comparative Agonist Case Studies and Formulations

  • Evaluation of Phenylethylamine Agonists:

    • Norepinephrine (NE): Direct agonist with α>β\alpha > \beta selectivity.

    • Epinephrine (E): Nonselective α,β1,β2\alpha, \beta_1, \beta_2 agonist.

    • Isoproterenol (ISO): Nonselective β1\beta_1 and β2\beta_2 agonist.

    • N-t-Butylnorepinephrine (Colterol): Selective β2\beta_2 agonist.

      • Safest drug choice for asthma among catecholamines due to β2\beta_2 selectivity without β1\beta_1 cardiac stimulation.

      • Exhibits the lowest inactivation rate by MAO\text{MAO} due to the bulky t-butylt\text{-butyl} group.

  • Phenylephrine Structure and Profile:

    • Structure: Contains a 3′-OH3'\text{-OH} group on the ring, a β-OH\beta\text{-OH} group, and an N-methylN\text{-methyl} group (lacks the 4′-OH4'\text{-OH} of Epinephrine).

    • Pharmacology: Selective α1\alpha_1 agonist with less overall α\alpha and β\beta potency than NE\text{NE}, but nearly zero β\beta activity.

    • Clinical Use: Available over-the-counter (OTC\text{OTC}) as a nasal decongestant.

    • Metabolism: Not a substrate for COMT\text{COMT}, conferring a longer DOA\text{DOA} than Epinephrine.

  • Epinephrine Formulations and Oxidation:

    • EpiPen® (Epinephrine Injection): Auto-injectors used for emergency treatment of life-threatening severe allergic reactions (anaphylaxis\text{anaphylaxis}) from insect bites, foods, and medications.

    • Oxidative Degradation: Epinephrine is easily oxidized ((O)(O)) to a quinone analog, which rapidly degrades into Adrenochrome (causing dark coloration in expired EpiPen® units).

  • Dipivefrin (Prodrug Approach):

    • Structure: Formed by the esterification of Epinephrine's catechol hydroxyl groups with two pivalic acid molecules (forming pivaloyl diesters).

    • Properties of Epinephrine: Easily oxidized, less lipophilic, poor corneal absorption/penetration, highly irritating to eyes when treating glaucoma.

    • Properties of Dipivefrin: Non-catechol ester prodrug. Inactive until hydrolyzed. Resistant to oxidation, highly lipophilic, exhibits superior ocular absorption and corneal penetration, and causes less eye irritation than Epinephrine.

    • Activation: Enzymatically hydrolyzed by corneal esterases to yield active Epinephrine inside the eye.

Selective Agonists: Imidazolines and Guanidines

  • Selective α1-Agonists\alpha_1\text{-Agonists} (Imidazolines):

    • General SAR: Consist of an aromatic moiety connected via a methylene bridge (Ar-CH2-\text{Ar-CH}_2\text{-}) to an imidazoline ring.

    • Key Compounds:

      • Naphazoline (Privine): OTC\text{OTC} ocular/nasal decongestant.

      • Tetrahydrozoline (Visine): OTC\text{OTC} ocular decongestant.

      • Oxymetazoline (Afrin): OTC\text{OTC} nasal decongestant.

    • Metabolism: Not substrates for MAO\text{MAO} or COMT\text{COMT}.

  • Selective α2-Agonists\alpha_2\text{-Agonists} (Guanidines & Imidazolines):

    • General SAR: Consist of an aromatic moiety connected via an amino bridge (Ar-NH-\text{Ar-NH-}) to an imidazoline ring or open guanidine group (-NH-C(=NH)-NH2\text{-NH-C(=NH)-NH}_2).

    • Key Compounds:

      • Clonidine (Catapres): pKa=8.0pK_a = 8.0. Stimulates central α2-receptors\alpha_2\text{-receptors} in the brain to reduce sympathetic tone, producing an antihypertensive effect.

      • Guanabenz: Guanidine derivative, pKa=13.6pK_a = 13.6 (completely ionized at physiological pH).

      • Guanfacine: Guanidine derivative (76%76\% ionized, 25%25\% non-ionized at pH 7.4). Stimulates central α2-receptors\alpha_2\text{-receptors} in the brain, producing an antihypertensive effect.

Short-Acting and Long-Acting Beta-2 Agonists

  • Short-Acting β2-Agonists (SABA)\beta_2\text{-Agonists (SABA)}:

    • Albuterol (Ventolin): Top 200 asthma drug featuring a 3′-CH2OH,4′-OH3'\text{-CH}_2\text{OH}, 4'\text{-OH} resorcinol-like pattern and an N-t-butylN\text{-t-butyl} group.

      • Log P=0.66\text{Log } P = 0.66

      • DOA=3 to 6 hours\text{DOA} = 3\text{ to }6\,\text{hours}

    • Levalbuterol: Pure (R)-enantiomer(R)\text{-enantiomer} of albuterol.

    • Pirbuterol: Pyridine-containing β2\beta_2 agonist.

    • Metabolism: 3′-hydroxymethyl3'\text{-hydroxymethyl} derivatives are primarily metabolized via sulfate conjugation.

  • Long-Acting β2-Agonists (LABA)\beta_2\text{-Agonists (LABA)}:

    • Salmeterol: Contains an extended lipophilic lipophilic tail attached to the amine.

      • Log P=3.66\text{Log } P = 3.66

      • DOA=12 hours\text{DOA} = 12\,\text{hours}

    • Lipophilicity Correlation: Drugs with higher lipophilicity (higher Log P\text{Log } P values) demonstrate prolonged tissue retention and significantly longer DOA\text{DOA}.

Adrenergic Receptor Antagonists (Alpha and Beta Blockers)

  • Quinazoline Selective α1-Blockers\alpha_1\text{-Blockers}:

    • Prazosin: DOA=4 to 6 hours\text{DOA} = 4\text{ to }6\,\text{hours}

    • Terazosin: DOA=>18 hours\text{DOA} = >18\,\text{hours}

    • Doxazosin: DOA=18 to 36 hours\text{DOA} = 18\text{ to }36\,\text{hours}

    • Clinical Indications: Used in the treatment of hypertension and benign prostatic hyperplasia (BPH\text{BPH}).

  • Selective α1A-Blockers\alpha_{1A}\text{-Blockers}:

    • Receptor distribution: α1A\alpha_{1A} adrenoceptor subtype is predominant in prostate tissue.

    • Tamsulosin (Flomax): Selective α1A\alpha_{1A} blocker used for BPH\text{BPH}.

    • Alfuzosin (Uroxatral): Selective α1A\alpha_{1A} blocker used for BPH\text{BPH}.

  • General SAR of β-Blockers\beta\text{-Blockers} (Aryloxypropanolamines):

    • Scaffold structural formula: Aryl-O-CH2-CH(OH)-CH2-NH-R\text{Aryl-O-CH}_2\text{-CH(OH)-CH}_2\text{-NH-R}.

  • Nonselective β-Blockers\beta\text{-Blockers}:

    • Propranolol (Inderal): Prototypical aryloxypropanolamine nonselective β-blocker\beta\text{-blocker}.

      • Log P=3.1\text{Log } P = 3.1

      • Widely used antihypertensive. High lipophilicity enables crossing of the blood-brain barrier, resulting in CNS\text{CNS} side effects (e.g., dizziness, confusion, depression).

    • Nadolol: Nonselective β-blocker\beta\text{-blocker}.

      • Log P=1.29\text{Log } P = 1.29

  • Selective β1-Blockers\beta_1\text{-Blockers} (Cardioselective):

    • Atenolol:

      • Log P=0.1\text{Log } P = 0.1

      • Highly hydrophilic structure results in significantly lower CNS\text{CNS} side effects (e.g., dizziness, confusion, depression) compared to propranolol.

    • Metoprolol: Selective β1-blocker\beta_1\text{-blocker}.

    • Bisoprolol: Selective β1-blocker\beta_1\text{-blocker}.